LUX-Lung 2 is a multicentre Phase II, randomised, open-label, single arm trial of afatinib in patients with advanced lung cancer that were untreated or progressed after one course of chemotherapy. Patients were tested for activating EGFR mutations prior to their inclusion in the trial. 129 male and female patients took part in the LUX-Lung 2 trial.
